Re: BIO CEO Slides Up
in response to
by
posted on
Feb 13, 2019 01:18PM
"OK.... but if that's how it is, then doesn't the time elapsed so far signal a ridiculously good outcome?"
Yes, but only if the accumulated number of patient years is currently greater than the originally projected/planned number of patient years. Patient years are more relevant than chronological time because it would accurately reflect enrollment and dropouts. BETonMACE was originally designed to give 3600 patient years (2400 patients with average 18 months dosing). How many patient years are we at now? Could be more than 3600. Could be less than 3600. Without this critical knowledge, it is impossible to interpret the what the current trial timeline means in terms of event rate and apabetalone effect.
BearDownAZ